Leaf Huang
Fortuna: 7 986 $ al 30/06/2026
Fortuna: 7 986 $ al 30/06/2026
Leaf Huang is the founder of Lipella Pharmaceuticals, Inc. which was founded in 2005.
He held the title of Director from 2005 to 2013.
Dr. Huang is also the founder of LipoGenics, Inc., RGene Therapeutics, Inc., OncoTrap, Inc. Dr. Huang earned a doctorate degree from Michigan State University.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 31/03/2025 | 69.443 ( 1,5 % ) | 7 986 $ | 30/06/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
LipoGenics, Inc.
LipoGenics, Inc. Food: Meat/Fish/DairyConsumer Non-Durables Manufactures dietary supplements | Fundador | 19/02/2010 |
RGene Therapeutics, Inc.
RGene Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Research and design of gene therapy | Fundador | 19/02/2010 |
| Empresas | Cargo | Fin |
|---|---|---|
OncoTrap, Inc.
OncoTrap, Inc. Miscellaneous Commercial ServicesCommercial Services Develops the medicine that induces or potentiates the immune response as a means to eradicate tumor burden | Fundador | - |
| LIPELLA PHARMACEUTICALS INC. | Fundador | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
| Empresas privadas | 5 |
|---|---|
Lipella Pharmaceuticals, Inc.
Lipella Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes lipid-based therapies for common bladder syndromes | Health Technology |
Michigan State University
Michigan State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
LipoGenics, Inc.
LipoGenics, Inc. Food: Meat/Fish/DairyConsumer Non-Durables Manufactures dietary supplements | Consumer Non-Durables |
RGene Therapeutics, Inc.
RGene Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Research and design of gene therapy | Commercial Services |
OncoTrap, Inc.
OncoTrap, Inc. Miscellaneous Commercial ServicesCommercial Services Develops the medicine that induces or potentiates the immune response as a means to eradicate tumor burden | Commercial Services |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.